Recombinant human deoxyribonuclease I

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2008, Pages 387-398

  Lazarus, Robert A ^a   Wagener, Jeffrey S ^b  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051800530     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (80)

1. Aitken ML, Burke W, McDonald G, et al. (1992). Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 267(14):1947-51.
2. Armstrong JB, White JC. (1950). Liquifaction of viscous purulent exudates by deoxyribonuclease. Lancet 2:739-42.
3. Baranovskii AG, Buneva VN, Nevinsky GA. (2004). Human deoxyribonucleases. Biochemistry (Mosc) 69(6):587-601.
4. Bataillon V, Lhermitte M, Lafitte JJ, et al. (1992). The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. J Antimicrob Chemother 29(5):499-508.
5. Campbell VW, Jackson DA. (1980). The effect of divalent cations on the mode of action of DNase I. The initial reaction products produced from covalently closed circular DNA. J Biol Chem, 255(8):3726-35.
6. Chen WJ, Liao TH. (2006). Structure and function of bovine pancreatic deoxyribonuclease . Protein Pept Lett 2006, 13(5):447-53.
7. Chernick WS, Barbero GJ, Eichel HJ. (1961). In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 27:589-96.
8. Cimmino M, Nardone M, Cavaliere M, et al. (2005). Dornase alfa as postoperative therapy in cystic fibrosis sinonasal diseas. Arch Otolaryngol Head Neck Surg 2005, 131(12):1097-101.
9. Cipolla D, Gonda I, Shire SJ. (1994). Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. Pharm Res 11(4):491-8.
10. Dasgupta B, King M. (1996). Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 22(3):161-6.
11. Davis JC, Jr., Manzi S, Yarboro C, et al. (1999). Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8(1):68-76.
12. Davoodian K, Ritchings BW, Ramphal R, et al. (1997). Gelsolin activates DNase I in vitro and cystic fibrosis sputum. Biochemistry 36(32):9637-41.
13. Eisenberg JD, Aitken ML, Dorkin HL, et al. (1997). Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 131(1.1):118-24.
14. Elkins MR, Robinson M, Rose BR, et al. (2006). Acontrolled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354(3):229-40.
15. Evans CJ, Aguilera RJ. (2003). DNase II: genes, enzymes and function. Gene 322:1-15.
16. Fuchs HJ, Borowitz DS, Christiansen DH, et al. (1994). Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331(10):637-42.
17. Geller DE, Eigen H, Fiel SB, et al. (1998). Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 25(2):83-7.
18. Gonda I. (1990). Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst 6(4):273-313.
19. Green JD. (1994). Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc. Hum Exp Toxicol 13(Suppl 1):S1-42.
20. Guggino WB, Stanton BA. (2006). New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7(6):426-36.
21. Hendriks T, de Hoog M, Lequin MH, et al. (2005). DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care 9(4):R351-6.
22. Hitchcock SE, Carisson L, Lindberg U. (1976). Depolymerization of F-actin by deoxyribonuclease I. Cell 7(4):531-42.
23. Hubbard RC, McElvaney NG, Birrer P, et al. (1992). A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 326(12):812-15.
24. Kabsch W, Mannherz HG, Suck D, et al. (1990). Atomic structure of the actin:DNase I complex. Nature 347(6288):37-44.
25. Kerem B, Rommens JM, Buchanan JA, et al. (1989). Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922):1073-80.
26. King M, Dasgupta B, Tomkiewicz RP, et al. (1997). Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 156(1):173-7.
27. Kominato Y, Ueki M, Iida R, et al. (2006). Characterization of human deoxyribonuclease I gene (DNASE1) promoters reveals the utilization of two transcriptionstarting exons and the involvement of Sp1 in its transcriptional regulation. FEBS J 273(13):3094-105.
28. Lachmann PJ. (2003). Lupus and desoxyribonuclease. Lupus 12(3):202-6.
29. Laskowski Sr. M. Deoxyribonuclease I. (1971). In: Boyer PD, ed. The Enzymes. 3rd ed., Vol. 4. New York: Academic Press, 289-311.
30. Laube BL, Auci RM, Shields DE, et al. (1996). Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 153(2):752-60.
31. Lazarides E, Lindberg U. (1974). Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 71(12):4742-6.
32. Lazarus RA. (2002). Human deoxyribonucleases. In:Creighton TE, ed. Wiley Encyclopedia of Molecular Medicine. New York: John Wiley and Sons, 1025-8.
33. Lieberman J. (1962). Enzymatic dissolution of pulmonary secretions. An in vitro study of sputum from patients with cystic fibrosis of pancreas. Am J Dis Child, 104:342-8.
34. Lieberman J. (1968). Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis.JAMA 205(5):312-13.
35. Manderson AP, Carlucci F, Lachmann PJ, et al. (2006). The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. Arthritis Res Ther 8(3):R68.
36. Matthews LW, Specter S, Lemm J, et al. (1963). The over-all chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectatis and laryngectomy. Am Rev Respir Dis 88:119-204.
37. McCoy K, Hamilton S, Johnson C. (1996). Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest, 110(4):889-95.
38. Mohler M, Cook J, Lewis D, et al. (1993). Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metab Dispos 21(1):71-5.
39. Moore S. (1981). Pancreatic DNase. In: Boyer PD, ed. The Enzymes, 3rd ed., Vol. 14. New York: Academic Press, 281-96.
40. Napirei M, Karsunky H, Zevnik B, et al. (2000). Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25(2):177-81.
41. Nasr SZ, Strouse PJ, Soskolne E, et al. (2001). Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 120(1):203-8.
42. O'Donnell AE, Barker AF, Ilowite JS, et al. (1998). Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 113(5):1329-34.
43. Pan CQ, Lazarus RA. (1997). Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism. Biochemistry 36(22):6624-32.
44. Pan CQ, Ulmer JS, Herzka A, et al. (1998a). Mutational analysis of human DNase I at the DNA binding interface:implications for DNA recognition, catalysis, and metal ion dependence. Protein Sci 7(3):628-36.
45. Pan CQ, Dodge TH, Baker DL, et al. (1998b). Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J Biol Chem 273(29):18374-81.
46. Pan CQ, Lazarus RA. (1999). Ca2-dependent activity of human DNase I and its hyperactive variant. Protein Sci 1999, 8(9):1780-8.
47. Pan CQ, Sinicropi DV, Lazarus RA. (2001). Engineered properties and assays for human DNase I mutants. Methods Mol Biol 160:309-21.
48. Potter JL, Specter S, Matthews LW, et al. (1969). Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis bronchiectasis and laryngectomy. Am Rev Respir Dis 99:909-15.
49. Prince WS, Baker DL, Dodge AH, et al. (1998). Pharmacodynamics of recombinant human DNase I in serum. Clin Exp Immunol 113(2):289-96.
50. Puterman AS, Weinberg EG. (1997). rhDNase in acute asthma. Pediatr Pulmonol 23(4):316-17.
51. Quan JM, Tiddens HA, Sy JP, et al. (2001). A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139(6):813-20.
52. Ramphal R, Lhermitte M, Filliat M, et al. (1988). The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 22(4):483-90.
53. Ramsey BW, Astley SJ, Aitken ML, et al. (1993). Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148(1):145-51.
54. Ramsey BW, Pepe MS, Quan JM, et al. (1999). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340(1):23-30.
55. Raskin P. (1968). Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 98(4):697-8.
56. Raynor EM, Butler A, Guill M, et al. (2000). Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. Arch Otolaryngol Head Neck Surg 126(5):581-3.
57. Riethmueller J, Borth-Bruhns T, Kumpf M, et al. (2006). Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol 41(1):61-6.
58. Riordan JR, Rommens JM, Kerem B, et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066-73.
59. Robinson M, Hemming AL, Moriarty C, et al. (2000). Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 30(1):16-24.
60. Saiman L, Mayer-Hamblett N, Campbell P, et al. (2005). Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172(8):1008-12.
61. Sanders NN, Franckx H, De Boeck K, et al. (2006). Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 61(11):962-8.
62. Shah PI, Bush A, Canny GJ, et al. (1995). Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 8(6):954-8.
63. Shak S, Capon DJ, Hellmiss R, et al. (1990). Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 87(23):9188-92.
64. Shak S. (1995). Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 107(2):65S-70S.
65. Shiokawa D, Tanuma S. (2001). Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry 40(1):143-52.
66. Shire SJ. (1996). Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme, (dornase alpha)]. In: Pearlman R, Wang YJ, eds. Pharmaceutical Biotechnology: Formulation, Characterization and Stability of Protein Drugs, Vol. 9. New York: Plenum Press, 393-426.
67. Simpson G, Roomes D, Reeves B. (2003). Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 58(4):365-6.
68. Sinicropi DV, Prince WS, Lofgren JA, et al. (1994a). Sputum pharmacodynamics and pharmacokinetics of recombinant human DNase I in cystic fibrosis. Am J Respir Crit Care Med 149(Suppl 1):A671.
69. Sinicropi DV, Baker DL, Prince WS, et al. (1994b). Colorimetric determination of DNase I activity with a DNA-methyl green substrate. Anal Biochem 222(2):351-8.
70. Sinicropi DV, Lazarus RA. (2001). Assays for human DNase I activity in biological matrices. Methods Mol Biol 160:325-33.
71. Suck D. (1994). DNA recognition by DNase I. J Mol Recognit 7(2):65-70.
72. Suri R. (2005). The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs 19(3):135-44.
73. Ulmer JS, Herzka A, Toy KJ, et al. (1996). Engineering actinresistant human DNase I for treatment of cystic fibrosis. Proc Natl Acad Sci USA 93(16):8225-9.
74. Vasconcellos CA, Allen PG, Wohl ME, et al. (1994). Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263(5149):969-71.
75. Wagener JS, Rock MJ, McCubbin MM, et al. (1998). Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. J Pediatr 133(4):486-91.
76. Widlak P, Garrard WT. (2005). Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 94(6):1078-87.
77. Wills PJ, Wodehouse T, Corkery K, et al. (1996). Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 154(2.1):413-17.
78. Wilmott RW, Amin RS, Colin AA, et al. (1996). Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 153(6.1):1914-17.
79. Wolf E, Frenz J, Suck D. (1995). Structure of human pancreatic DNase I at 2.2 A ° resolution. Protein Eng 8 (Suppl):79.
80. Zahm JM, Girod de Bentzmann S, Deneuville E, et al. (1995). Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J 8(3):381-6.